Search clinical trials for: MK 3475

Total 3316 results

Merck Sharp & Dohme LLC

Terminated

The Effect of MK0633 in Patients With Chronic Asthma (0633-007)

Asthma
Merck Sharp & Dohme LLC

Completed

Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

Arthritis, Rheumatoid
Merck Sharp & Dohme LLC

Terminated

MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)

HIV-1 Infection
Merck Sharp & Dohme LLC
Actelion

Completed

A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)

Hypertension
Merck Sharp & Dohme LLC

Completed

MK0524 Asthma POC Study (0524-008)(COMPLETED)

Asthma
Merck Sharp & Dohme LLC

Withdrawn

Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

Chronic Hepatitis C
Cancer Research UK

Completed

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Cancer

United Kingdom
Merck Sharp & Dohme LLC

Withdrawn

Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145) (MRS Tumor)

Glioma
Merck Sharp & Dohme LLC

Completed

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

Diabetes Mellitus Type 2
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) (SUPPORT)

Substance Abuse, Intravenous | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)

Atherosclerotic Vascular Disease
Merck Sharp & Dohme LLC

Completed

The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)

Hypertension
Meir Medical Center

Completed

Camel's Milk as a Safe Alternative in Cow's Milk Allergy

Cow's Milk Allergy

Israel
Merck Sharp & Dohme LLC

Completed

Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)

Hypercholesterolemia, Dyslipidemia
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)

Healthy | Obesity | Overweight
Merck Sharp & Dohme LLC

Completed

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

Thrombosis
Merck Sharp & Dohme LLC

Completed

Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED) (MCAT)

Carotid Atherosclerosis
Merck Sharp & Dohme LLC

Terminated

Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)

Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
National Cancer Institute (NCI)

Completed

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

Colorectal Neoplasms

United States
Merck Sharp & Dohme LLC

Terminated

Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) (ACHIEVE)

Hypercholesterolemia, Familial
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

Healthy

Belgium
Merck Sharp & Dohme LLC

Completed

A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)

Smoking
Revalesio Corporation

Completed

Systemic Bioactivity of Inhaled Nebulized RNS60

Systemic Bioactivity of Nebulized RNS60

United Kingdom
Merck Sharp & Dohme LLC

Terminated

Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)

Hypertension | Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

Myelodysplastic Syndromes | Leukemia, Myelocytic, Acute Myelodysplastic Syndromes
Merck Sharp & Dohme LLC

Terminated

Dose-Range Finding Study for MK0893 (0893-008)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Early Airway Response to Allergen in Asthmatics (MK-0000-176)

Asthma
Merck Sharp & Dohme LLC

Completed

A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)

Asthma
Merck Sharp & Dohme LLC

Completed

A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Cholesterol Levels (0524A-048)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

Type 2 Diabetes Mellitus
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States
Merck Sharp & Dohme LLC

Terminated

A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors

United States
Merck Sharp & Dohme LLC

Completed

A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)

Tumors
Merck Sharp & Dohme LLC

Completed

A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)

Hypertension
Merck Sharp & Dohme LLC

Completed

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Breast Cancer | Breast Neoplasms
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors
Merck Sharp & Dohme LLC

Completed

A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199) (SIRTA)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Osteoporosis | Postmenopausal Osteoporosis
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer

3

Subscribe